Literature DB >> 16123535

Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.

Marko Pesu1, John O'Shea, Lothar Hennighausen, Olli Silvennoinen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16123535     DOI： 10.1124/mi.5.4.4

Source DB:  PubMed          Journal:  Mol Interv        ISSN： 1534-0384


× No keyword cloud information.
  4 in total

1.  The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.

Authors:  Maurizio Cutolo
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-02       Impact factor: 5.346

2.  JAK Kinases in Health and Disease: An Update.

Authors:  Arian Laurence; Marko Pesu; Olli Silvennoinen; John O'Shea
Journal:  Open Rheumatol J       Date:  2012-09-07

3.  Kinase inhibitors in the treatment of immune-mediated disease.

Authors:  Apostolos Kontzias; Arian Laurence; Massimo Gadina; John J O'Shea
Journal:  F1000 Med Rep       Date:  2012-03-01

4.  Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation.

Authors:  Alireza Moradabadi; Alireza Farsinejad; Behzad Khansarinejad; Ahamd Fatemi
Journal:  Exp Hematol Oncol       Date:  2019-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.